What is Competitive Landscape of ResMed Company?

ResMed Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

How does ResMed maintain its lead in sleep and respiratory care?

ResMed scaled from CPAP machines to a global, connected respiratory ecosystem by integrating devices, masks, ventilators and cloud software. In FY2024 it reported revenue near $4.5–5.0 billion and >20 million cloud‑connected devices, powering remote care at scale.

ResMed competes through product breadth, SaaS-enabled care, strong distribution across 160+ countries and data‑driven clinical outcomes; key rivals include Philips Respironics, Fisher & Paykel Healthcare and smaller niche players. See ResMed Porter's Five Forces Analysis for structural industry forces.

ResMed designs and sells devices and software for sleep-disordered breathing and out-of-hospital care, combining connected CPAP/BiPAP/ventilator hardware with cloud platforms and SaaS to improve adherence, clinical outcomes, and payor value.

Global share in masks

Industry and sell-side estimates for 2024 place ResMed at roughly 55–60% global share in masks, led by the AirFit families.

Flow generator position

Estimated global share in flow generators (CPAP/APAP/BiPAP) was about 45–50% in 2024, with AirSense and AirCurve lines occupying leading-to-co-leading slots.

Digital and SaaS footprint

Over 85–90% of new devices ship cloud-connected (AirView, myAir); complementary SaaS includes Brightree and MatrixCare for out-of-hospital care management.

Financial profile (FY2024)

FY2024 revenue exceeded $4.8–5.2 billion; operating margins were in the mid-20s percent range and R&D ran near 7–8% of sales.

Regional strength is concentrated in North America (notably the U.S. homecare channel), Australia and parts of Western Europe, while emerging markets show lower penetration due to price sensitivity and local competitors.

Competitive dynamics and recent shifts

Market positioning improved after a major competitor recall in 2021–2023, which tightened supply and allowed share gains; competition normalized as supply returned in 2024–2025.

• ResMed competitive landscape: strengthened by integrated hardware-plus-software model.
• ResMed market competition: faces Philips Respironics, Fisher & Paykel Healthcare, and regional players in APAC/EMEA.
• ResMed competitors: pressure from restored supplies post-recall and pricing in emerging markets.
• Cloud-connected advantage: connected devices boost adherence metrics and payer contracting leverage.

For a deeper comparison and market-share context, see Competitors Landscape of ResMed

ResMed SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

ResMed derives revenue from device sales (CPAP, APAP, BiPAP, ventilators), recurring consumables (masks, tubing, filters) and subscription software/services (cloud connectivity, remote patient management). In 2024 ResMed reported $4.9B in revenue, with recurring consumables and software contributing a growing share of margin and customer lifetime value.

Monetization emphasizes device-plus-subscription bundles, DME channel relationships, and growing digital-therapeutics engagements that increase stickiness and service revenue.

Philips Respironics resurgence

After the 2021 recall Philips lost share; by 2024–2025 production recovery increased competitive intensity on devices, pricing and replenishment programs.

Fisher & Paykel Healthcare

Competes on premium mask comfort, humidification and hospital respiratory solutions; strong R&D cadence and growing homecare footprint.

Regional challengers

Teijin, Nidek (select markets), Löwenstein Medical and Drive DeVilbiss pressure prices and service in Europe and Asia with localized offerings.

Hospital/acute ventilator ecosystems

Medtronic, Hamilton Medical and GE HealthCare impact referral pathways and standards via ventilation platforms and integrated data systems.

Digital and DTx entrants

Remote screening, OTC wearables and at‑home diagnostics shift funnel dynamics; software vendors and DME consolidations alter channel power.

Market-share dynamics 2022–2025

ResMed captured meaningful share gains during Philips’ recall window (2022–2024); 2024–2025 saw intensified pricing competition and mask replenishment battles as supply normalized.

Key competitive considerations for ResMed include channel relationships with DMEs, pricing pressure on devices and consumables, and the impact of software-enabled care pathways; see company context in Brief History of ResMed.

Competitive snapshot

Fast facts and tactical threats to monitor in the ResMed competitive landscape and market competition.

• Philips regained production by 2024–2025, increasing device and pricing competition
• Fisher & Paykel wins on mask comfort and hospital-grade humidification
• Regional makers compete on cost and service in Europe/Asia
• Digital entrants and DTx shift diagnosis-to-treatment funnel and channel power

ResMed PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Key milestones include scaling to tens of millions of cloud‑connected devices and building one of the largest respiratory datasets, frequent product refresh cycles in masks, and post‑pandemic capacity expansion that improved fulfillment and resilience.

Strategic moves: integration of SaaS with U.S. DME channels (Brightree, MatrixCare), heavy investment in clinical studies linking adherence to cardiovascular and metabolic outcomes, and continued R&D in mask fit and device connectivity.

Connected ecosystem scale

Cloud‑connected devices and the myAir/AirView platforms leverage a respiratory dataset measured in tens of millions of nights to power adherence algorithms and clinician workflows, improving outcomes and payer acceptance.

Mask innovation & replenishment

The AirFit portfolio, frequent refresh cycles, and fit/comfort IP create high‑margin recurring revenue; mask replenishment drives aftermarket sales and switching costs for users and providers.

Channel depth in U.S. homecare

Deep DME relationships plus integrated SaaS (Brightree, MatrixCare) streamline documentation, resupply, and billing, increasing customer lifetime value and reducing churn in the U.S. market.

Operational scale & supply chain

Post‑2020 investments expanded manufacturing capacity and component resilience, enabling faster recovery and fulfillment during competitor shortages and supporting global market share retention.

Clinical evidence and payer alignment strengthen reimbursement; studies cited by the company tie improved adherence to reduced comorbidity costs, supporting market positioning across North America and Europe and aiding negotiations with insurers.

Moats, risks and strategic implications

Core competitive advantages rest on data network effects and channel software integration, but pressures persist from commoditization, renewed competitor product launches, and shifting therapy demand.

• Connected data moat: myAir and AirView increase clinical stickiness and payer acceptance in the sleep apnea device market.
• Replenishment economics: mask portfolio and high refresh cadence generate recurring high‑margin revenue and switching costs.
• Channel & software tie‑ins: U.S. DME integrations with Brightree/MatrixCare improve resupply and billing efficiency.
• Supply resilience: expanded capacity reduces outage risk and allows market share gains during competitor disruptions.

For further context on corporate strategy and values see Mission, Vision & Core Values of ResMed.

ResMed Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

ResMed's industry position rests on a data-rich, software-enabled respiratory platform and a strong mask franchise that together mitigate risks from device price pressure and evolving care pathways; key risks include increased price competition as full competitors re-enter, regulatory scrutiny raising compliance costs, and DME consolidation squeezing commercial terms. The future outlook favors growth in connected care, home ventilation, and software monetization but requires capacity flexibility, selective M&A and partnerships, and continued adherence-driven economics to defend market share.

Industry trend — diagnosis and adherence

At‑home sleep testing and payer focus on CPAP adherence are expanding diagnosed patient pools and shifting reimbursement toward outcomes; global CPAP market growth is forecast in the mid‑single to low‑double digits CAGR through 2028, with masks outpacing devices on recurring revenue.

Digital and integration momentum

Integration of respiratory devices with EHRs and remote patient monitoring, plus AI‑driven coaching and adherence analytics, is increasing software monetization potential and stickiness of cloud services like AirView.

Regulatory & quality environment

Tightened device safety scrutiny after recalls raises compliance costs and creates higher barriers to entry, benefiting established players with robust quality systems but compressing margins industry‑wide.

Market structure and competition

With full competitor supply returning, ResMed faces renewed pricing pressure from CPAP and BiPAP competitors while masks and resupply programs remain a defensive margin lever; component cost volatility and DME consolidation add commercial headwinds.

GLP‑1 weight‑loss drugs sparked debate in 2024–2025 about reduced OSA prevalence; current analyses indicate only a partial offset because a large prevalent and undiagnosed pool remains (estimates exceed 900 million globally with OSA symptoms), and adherence‑driven value is likely to keep demand resilient while moderating long‑term growth assumptions.

Future challenges and opportunities

Near‑term and medium‑term competitive dynamics will be shaped by pricing, regulation, and digital service adoption; ResMed's strengths create opportunities but also require strategic responses.

• Opportunity: penetrate emerging markets in Asia and Latin America where CPAP adoption remains under-penetrated and demographic trends (aging populations) support growth.
• Opportunity: expand software monetization via AirView and adherence analytics; subscription and value‑based contracts with payers/providers can lift lifetime revenue per patient.
• Opportunity: grow home ventilation for COPD and integrated care partnerships that bundle devices, monitoring and care coordination.
• Challenge: renewed price competition from returning rivals and new entrants may pressure ASPs for devices; masks and resupply help protect recurring margins.
• Challenge: component cost volatility and supply‑chain risks can compress gross margins absent sourcing flexibility.
• Challenge: DME consolidation and tighter payer negotiations can reduce commercial leverage and lengthen sales cycles.
• Challenge: consumer adoption of lower‑cost or OTC screening pathways could change referral patterns and channel economics.

ResMed's competitive positioning — combining device hardware, mask leadership, cloud services and provider/payer relationships — supports defense of share in the global sleep apnea device market and positions the company to expand in ventilation and digital care; see a focused discussion in Growth Strategy of ResMed.

ResMed Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔